非小細胞肺癌治療市場規模、佔有率和成長分析：按治療方法、癌症類型、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球非小細胞肺癌治療市場價值為 398 億美元，預計從 2025 年的 421 億美元成長到 2033 年的 660.5 億美元，預測期（2026-2033 年）的複合年成長率為 5.79%。

全球非小細胞肺癌 (NSCLC) 治療市場涵蓋多種療法，包括標靶治療、免疫療法和化療，所有這些療法都旨在改善患者預後並延長存活期。 NSCLC 的高發病率、與該疾病相關的巨額醫療費用以及公共和私營部門持續的研究經費是推動該市場成長的主要因素。利用生物標記識別突變的個人化醫療技術的進步正在革新治療方法，實現更有效的藥物標靶化，並提高奧希替Osimertinib和Alectinib等藥物的應用率。此外，人工智慧技術在藥物研發中的應用正在簡化標靶識別和分子構建等流程，進一步加速 NSCLC 藥物領域的創新。

全球非小細胞肺癌治療市場的成長要素

全球非小細胞肺癌 (NSCLC) 治療市場的主要促進因素之一是肺癌在全球範圍內的發病率不斷上升，這歸因於吸煙、環境污染和遺傳易感性等因素。發病率的上升推動了對有效治療方法的需求，並加速了標靶治療療法和免疫療法的研發。此外，精準醫療的進步和新型生物標記的出現使得更個人化的治療方案成為可能，從而改善了患者的治療效果。人們對肺癌的認知不斷提高以及對醫療基礎設施的持續投入，進一步促進了創新治療方法的普及，並推動了市場成長。

全球非小細胞肺癌治療市場的限制因素

全球非小細胞肺癌 (NSCLC) 治療市場的主要限制因素之一是創新治療方法的高成本。高標靶治療和免疫療法的經濟負擔可能對患者和醫療系統造成過重壓力，導致相當一部分患者無法接受治療。此外，保險報銷方面的挑戰和覆蓋範圍的差異也造成了治療機會的不平等。治療方法的複雜性和個人化醫療的需求進一步加劇了患者管理的難度，可能導致必要的治療被延遲或放棄，最終阻礙市場整體成長和患者療效。

全球非小細胞肺癌治療市場趨勢

全球非小細胞肺癌（NSCLC）治療市場正呈現出聯合治療顯著擴張的趨勢，尤其是免疫療法與其他治療方法的聯合應用。生物製藥公司正日益探索將免疫療法與血管生成抑制劑及其他藥物聯合使用的潛在協同效應，以應對癌症抗藥性和異質性等複雜挑戰。這一趨勢凸顯了基於生物標記的亞組選擇、適應性試驗設計以及有效的生命週期管理策略對於在競爭激烈的市場環境中實現產品差異化的重要性。然而，包括支付方和醫療服務提供者在內的相關人員，要求提供強力的證據，證明這些創新治療方法具有持續的療效和安全性，以確保其有效性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球非小細胞肺癌治療市場規模：依治療類型分類

• 標靶治療
  • EGFR抑制劑
  • ALK抑制劑
  • ROS1抑制劑
  • KRAS抑制劑
  • BRAF抑制劑
  • MET抑制劑
  • RET抑制劑
  • HER2抑制劑
• 免疫療法
  • PD-1抑制劑
  • PD-L1抑制劑
  • CTLA-4抑制劑
• 化療
  • 含鉑類藥物類化療
  • 抗代謝物
  • 微管抑制劑
• 抗血管新生療法
• 聯合治療

全球非小細胞肺癌治療市場規模：依癌症類型分類

• 腺癌
• 鱗狀細胞癌
• 大細胞癌

全球非小細胞肺癌治療藥物市場規模：依給藥途徑分類

• 口服
• 注射藥物/靜脈注射

全球非小細胞肺癌治療市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 專科藥房
• 網路藥房

全球非小細胞肺癌治療市場規模：依最終用戶分類

• 醫院
• 癌症治療中心
• 門診手術中心
• 專科診所

全球非小細胞肺癌治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AstraZeneca PLC
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson Innovative Medicine
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• BeiGene, Ltd.
• Regeneron Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• Exelixis, Inc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Blueprint Medicines Corporation
• Jazz Pharmaceuticals plc

結論與建議

Global Non-Small Cell Lung Cancer Therapeutics Market size was valued at USD 39.8 Billion in 2024 and is poised to grow from USD 42.1 Billion in 2025 to USD 66.05 Billion by 2033, growing at a CAGR of 5.79% during the forecast period (2026-2033).

The global Non-Small Cell Lung Cancer (NSCLC) therapeutics market encompasses a variety of treatment options, including targeted therapies, immunotherapies, and chemotherapy, aimed at improving patient outcomes and extending survival. The market's growth is driven by the high prevalence of NSCLC, significant healthcare costs associated with the disease, and ongoing funding for research from both public and private sectors. Advances in personalized therapy using biomarkers for mutation identification have revolutionized treatment approaches, enabling more effective drug targeting and enhancing adoption rates for medications like osimertinib and alectinib. Additionally, the integration of AI technologies in drug discovery is streamlining processes such as target identification and molecule creation, further propelling innovation in the NSCLC pharmaceutical landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Small Cell Lung Cancer Therapeutics Market Segments Analysis

Global non-small cell lung cancer therapeutics market is segmented by therapy type, cancer type, route of administration, distribution channel, end user and region. Based on therapy type, the market is segmented into Targeted Therapy, Immunotherapy, Chemotherapy, Anti-Angiogenic Therapy and Combination Therapy. Based on cancer type, the market is segmented into Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma. Based on route of administration, the market is segmented into Oral and Injectable/Intravenous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Treatment Centers, Ambulatory Surgical Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Small Cell Lung Cancer Therapeutics Market

One of the key market drivers for the global non-small cell lung cancer (NSCLC) therapeutics market is the rising prevalence of lung cancer globally, largely due to factors such as smoking, environmental pollutants, and genetic predispositions. This increasing incidence heightens the demand for effective treatment options, spurring research and development in targeted therapies and immunotherapies. Moreover, advancements in precision medicine and the emergence of novel biomarkers enable more personalized treatment approaches, resulting in improved patient outcomes. The growing awareness of lung cancer and ongoing investment in healthcare infrastructure further facilitate access to innovative therapies, fueling market growth.

Restraints in the Global Non-Small Cell Lung Cancer Therapeutics Market

One significant market restraint for the Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market is the high cost associated with innovative treatments and therapies. The financial burden of advanced targeted therapies and immunotherapies can be prohibitive for patients and healthcare systems, leading to limited access for a substantial segment of the population. Additionally, reimbursement challenges and varying levels of insurance coverage create disparities in treatment accessibility. The complexity of treatment regimens and the necessity for personalized medicine further complicate patient management, potentially resulting in delays or avoidance of necessary therapy, ultimately hindering overall market growth and patient outcomes.

Market Trends of the Global Non-Small Cell Lung Cancer Therapeutics Market

The Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics market is witnessing a significant trend towards the expansion of combination therapies, particularly utilizing immunotherapy drugs alongside other treatment modalities. Biopharma companies are increasingly exploring the synergetic potential of combining immunotherapies with angiogenesis inhibitors and other agents to tackle the complexities of cancer resistance and heterogeneity. This trend emphasizes the importance of biomarker subgroup selection, adaptive trial designs, and effective lifecycle management strategies to differentiate products in a competitive landscape. However, stakeholders, including payers and providers, are insisting on robust evidence highlighting sustained benefits and safety profiles, ensuring the viability of these innovative therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-small Cell Lung Cancer Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
  • EGFR Inhibitors
  • ALK Inhibitors
  • ROS1 Inhibitors
  • KRAS Inhibitors
  • BRAF Inhibitors
  • MET Inhibitors
  • RET Inhibitors
  • HER2 Inhibitors
• Immunotherapy
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
• Chemotherapy
  • Platinum-Based Chemotherapy
  • Antimetabolites
  • Microtubule Inhibitors
• Anti-Angiogenic Therapy
• Combination Therapy

Global Non-small Cell Lung Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

Global Non-small Cell Lung Cancer Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable/Intravenous

Global Non-small Cell Lung Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Non-small Cell Lung Cancer Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Specialty Clinics

Global Non-small Cell Lung Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Innovative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations